Shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) have received a consensus rating of "Hold" from the thirteen analysts that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $22.00.
MYGN has been the subject of a number of research reports. UBS Group assumed coverage on Myriad Genetics in a research note on Tuesday, December 10th. They issued a "neutral" rating and a $18.00 price target for the company. Leerink Partnrs downgraded Myriad Genetics from a "strong-buy" rating to a "hold" rating in a report on Monday, December 9th. The Goldman Sachs Group dropped their price target on Myriad Genetics from $29.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Bank of America decreased their price objective on shares of Myriad Genetics from $15.00 to $13.00 and set an "underperform" rating for the company in a report on Friday, December 13th. Finally, Leerink Partners cut shares of Myriad Genetics from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $30.00 to $21.00 in a report on Monday, December 9th.
Get Our Latest Analysis on Myriad Genetics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MYGN. Nordea Investment Management AB increased its stake in Myriad Genetics by 117.0% in the 4th quarter. Nordea Investment Management AB now owns 332,913 shares of the company's stock valued at $4,548,000 after buying an additional 179,527 shares during the period. State of New Jersey Common Pension Fund D purchased a new position in shares of Myriad Genetics during the 3rd quarter valued at $1,965,000. Jennison Associates LLC increased its stake in shares of Myriad Genetics by 144.2% in the fourth quarter. Jennison Associates LLC now owns 59,015 shares of the company's stock worth $809,000 after acquiring an additional 34,853 shares during the last quarter. Barclays PLC raised its holdings in shares of Myriad Genetics by 136.9% during the third quarter. Barclays PLC now owns 190,243 shares of the company's stock worth $5,210,000 after acquiring an additional 109,931 shares in the last quarter. Finally, Simplify Asset Management Inc. acquired a new stake in Myriad Genetics during the third quarter valued at $4,756,000. Institutional investors and hedge funds own 99.02% of the company's stock.
MYGN stock opened at $12.41 on Monday. The company has a market capitalization of $1.13 billion, a PE ratio of -9.55 and a beta of 1.88. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The stock's 50 day moving average is $13.74 and its two-hundred day moving average is $20.40. Myriad Genetics has a 52-week low of $12.04 and a 52-week high of $29.30.
Myriad Genetics (NASDAQ:MYGN - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.08). The company had revenue of $213.30 million for the quarter, compared to the consensus estimate of $209.82 million. Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. During the same quarter last year, the company earned ($0.17) earnings per share. Analysts predict that Myriad Genetics will post -0.3 earnings per share for the current fiscal year.
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Myriad Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list.
While Myriad Genetics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.